Monopar Therapeutics Inc. (MNPR) Stock Grade

About Monopar Therapeutics Inc.'s fundamentals

Monopar Therapeutics is a biotechnology company with a market capitalization of $560.8 million that reported no revenue growth year-over-year and posted a net loss in its latest annual statement, resulting in a net margin of 0.0%. The company does not currently pay a dividend. Traditional valuation metrics like P/E ratio and return on equity are not applicable due to the company's unprofitable status, which is typical for early-stage biotech firms still in development phases.